OverviewChartNewsTraderScreen

ENTERA BIO IS-,0000769/  IL0011429839  /

Frankfurt
2024-04-26  8:02:26 AM Chg. -0.0600 Volume Bid9:59:40 PM Ask9:59:40 PM High Low
1.8300EUR -3.17% 0
Turnover: 0.0000		 -Bid Size: - -Ask Size: - 1.8300 1.8300
GlobeNewswire 04-08 Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the...
GlobeNewswire 03-26 Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FD...
GlobeNewswire 03-20 Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire 03-08 Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
GlobeNewswire 03-04 Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire 01-30 Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GlobeNewswire 01-03 Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
GlobeNewswire 2023-12-26 Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
GlobeNewswire 2023-11-29 Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatme...
GlobeNewswire 2023-11-14 Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision a...
GlobeNewswire 2023-11-09 Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-...
GlobeNewswire 2023-10-16 Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for ...
GlobeNewswire 2023-09-12 Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations f...
GlobeNewswire 2023-09-05 Entera Bio to Participate in Upcoming Investor Conferences
GlobeNewswire 2023-08-16 Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablet...
GlobeNewswire 2022-03-08 Entera Bio Reports Financial Results for the Year Ended December 31, 2021
GlobeNewswire 2022-03-03 Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8,...
GlobeNewswire 2022-02-17 Entera Bio to Present at Aegis Virtual Conference on February 23rd
GlobeNewswire 2022-01-04 Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve ...
GlobeNewswire 2021-11-10 Entera Bio Reports Third Quarter 2021 Financial Results
GlobeNewswire 2021-10-28 Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs
GlobeNewswire 2021-10-06 Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at L...
GlobeNewswire 2021-09-01 Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBM...
GlobeNewswire 2021-08-23 Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021
GlobeNewswire 2021-08-23 Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference